TransCode Therapeutics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsTransCode Therapeutics is a clinical-stage immuno-oncology company developing RNA-based and vaccine therapies for advanced cancers.
What they do
TransCode is developing TTX-MC138, a therapeutic targeting microRNA-10b in metastatic tumors, and Seviprotimut-L, a polyvalent antigen vaccine for stage IIB/IIC melanoma acquired via the Polynoma acquisition. The company has completed a Phase 0 trial and is evaluating Phase I/II data for TTX-MC138, with a Phase 2a planned. It also issued contingent value rights tied to future payments from these programs.
Revenue drivers
- TTX-MC138 — Lead therapeutic candidate for metastatic tumors overexpressing microRNA-10b; no revenue yet, all clinical stage.
- Seviprotimut-L — Investigational melanoma vaccine acquired in October 2025; potential future revenue only if approved.
- Contingent Value Rights (CVRs) — Holders entitled to 50% of net proceeds from any upfront or milestone payments received during a seven-year term.
Recent performance
Net loss widened to $34.7 million in 2025 from $16.8 million in 2024, and operating cash outflow increased to $19.5 million from $13.3 million. As of March 31, 2026, the company had $12.8 million in cash, total assets of $157.2 million, and shareholder equity of $1.3 million. The Phase I/II trial for TTX-MC138 substantially met its primary safety endpoint by the end of 2025, with analysis ongoing.
Strategy
Management plans to advance TTX-MC138 into a Phase 2a trial in the first half of 2026 while also developing Seviprotimut-L. The company acquired Polynoma in October 2025 to add the melanoma vaccine and issued $25 million in preferred stock to fund operations. They intend to explore combining the two assets to address micrometastases in stage IIB/IIC melanoma.
Risks
- Cash runway — Cash of $12.8 million against operating losses of ~$19.5 million annually suggests limited funding horizon.
- Equity dilution — Series A and B preferred stock are convertible into common stock at 10,000 shares each, which will significantly dilute existing holders.
- Clinical failure — TTX-MC138 has only completed a one-patient Phase 0 trial and a Phase I/II that met its primary safety endpoint; efficacy is unproven.
- Nasdaq delisting risk — An 8-K dated May 26, 2026 indicates a delisting notice or listing-rule failure, and the stock's market value was only ~$6.5 million in June 2025.
Outlook
Management expects to commence a Phase 2a trial for TTX-MC138 in the first half of 2026. The Polynoma acquisition adds Seviprotimut-L, with plans to develop both programs. The company faces near-term funding needs and potential delisting concerns.